A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of MEDI9447 (Oleclumab) in Japanese Patients with Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 09 Jul 2019
Price : $35 *
At a glance
- Drugs Oleclumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 04 Jul 2019 Status changed from active, no longer recruiting to completed.
- 06 Jun 2019 Planned End Date changed from 23 Jul 2019 to 25 Jun 2019.
- 06 Jun 2019 Planned primary completion date changed from 23 Jul 2019 to 25 Jun 2019.